Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 1059-1067

  Greally, Peter ^a   Whitaker, Paul ^b   Peckham, Daniel ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa; Treatment burden

Indexed keywords

AMIKACIN; AMITRIPTYLINE; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM LYSINE; BRAMITOB; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; FOSFOMYCIN; GILEAD; LEVOFLOXACIN; MACROLIDE; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CHRONIC PSEUDOMONAS AERUGINOSA INFECTION; CLINICAL PRACTICE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG USE; ERADICATION THERAPY; EXERCISE; HEALTH CARE; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MEDLINE; NEBULIZER; PATIENT COMPLIANCE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PSEUDOMONAS INFECTION; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84862523978     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.674500     Document Type: Review

References (94)

1. Patient Registry Annual Data Report 2009. Cystic Fibrosis Foundation, 2009. Available at: http://www.cff.org/UploadedFiles/research/ClinicalResearch/ Patient-Registry-Report-2009.pdf [Last accessed 26 September 2011]
2. Brennan AL, Geddes DM. Cystic fibrosis. Curr Opin Infect Dis 2002; 15:175-82
3. Geller DE, Rubin BK. Respiratory care and cystic fibrosis. Respir Care 2009;54:796-800
4. Zemanick ET, Harris JK, Conway S, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2010;9:1-16
5. Braccini G, Festini F, Boni V, et al. The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Chemother 2009;21:188-92
6. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 2009;54:628-38
7. Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 2010;5:1663-74
8. Lillquist YP, Cho E, Davidson AG. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J Cyst Fibros 2011;10:175-80
9. Lee TW. Eradication of early Pseudomonas infection in cystic fibrosis. Chron Respir Dis 2009;6:99-107
10. Ratjen F, Munck A, Kho P, et al. Treatment with early Pseudomonas aerugi-nosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286-91
11. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28:159-66
12. Starner TD, McCray Jr PB. Pathogenesis of early lung disease in cystic fibro-sis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005; 143:816-22
13. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-61
14. 1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998;53:732-7
15. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009;54:658-69
16. Foweraker JE, Laughton CR, Brown DF, et al. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother 2009; 53:4809-15
17. Stuart B, Lin JH, Mogayzel Jr PJ. Early eradication of Pseudomonas aerugi-nosa in patients with cystic fibrosis. Paed Respir 2010;11:177-8
18. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeru-ginosa infection. J Cyst Fibros 2005;4(Suppl 2):49-54
19. Döring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3: 67-91
20. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Pediatr Pulmonol 1998;25:88-92
21. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-69
22. Döring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-67
23. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30
24. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8
25. Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45:1121-34
26. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23:330-5
27. Lee TW, Brownlee KG, Denton M, et al. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004;37:104-10
28. Ho S-A, Lee TWR, Denton M, et al. Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cystic Fibrosis 2009;8:43-6
29. Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aerugi-nosa. J R Soc Med 2002;95(Suppl 41):22-6
30. Jones AM, Govan JRW, Doherty CJ, et al. Increased treatment requirements of cystic fibrosis patients who harbour a highly transmissible strain of Pseudomonas aeruginosa. Thorax 2002;57:924-5
31. Hayes Jr D, West SE, Rock MJ, et al. Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes. Pediatr Pulmonol 2010;45:708-16
32. McKay KO, Cooper PJ, van Asperen PP. Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aerugi-nosa. J Cyst Fibros 2009;8:400-4
33. Jones AM, Dodd ME, Govan JRW, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a Cystic Fibrosis Center. Am J Respir Crit Care Med 2005;171:257-60
34. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26:458-61
35. Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 2009:8:361-9
36. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7:523-30
37. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC Clinical Trial and Observational Study. Contemp Clin Trials 2009; 30:256-68
38. Gilligan PH. Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis? Expert Rev Anti Infect Ther 2006;4:711-15
39. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-51
40. Brown SMN, Balfour-Lynn IM. Duration of intravenous antibiotic treatment for respiratory exacerbations in children with cystic fibrosis. Arch Dis Child 2010;95:568
41. Flume PA, Mogayzel Jr PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8
42. Moskowitz SM, Silva SJ, Mayer-Hamblett N, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008;43:874-81
43. Stephens D, Garey N, Isles A, et al. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983;2:209-11
44. Schaad UB, Wedgwood-Krucko J, Suter S, et al. Efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605
45. Semsarian C. Efficacy of inhaled tobramycin in cystic fibrosis. J Paediatr Child Health 1990;26:110-11
46. Conway SP. Nebulized antibiotic therapy: the evidence. Chron Respir Dis 2005;2:35-41
47. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;CD001021
48. Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007;42:307-13
49. MacLeod DL, Nelson LE, Shawar RM, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 2000; 181:1180-4
50. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009;8:295-315
51. TOBI (tobramycin) Prescribing information. Available at: http://www.tobiti-me.com/info/tools/prescribing.jsp [Last accessed 26 September 2011]
52. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63
53. Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002;33:269-76
54. Stass H, Baumann-Noss S, Delesen H, et al. Pharmacokinetics of ciproflox-acin Pulmo-Sphere inhalational powder. J Cyst Fibros 2008;7:S26. Abstract 103
55. Westerman EM, De Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros 2007;6:284-92
56. Westerman EM, de Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm 2007;335:41-5
57. Westerman EM, Heijerman HG, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin Drug Deliv 2007;4:91-4
58. Wilson J, Moorehead L, Montgomery B. A phase 1 open label trial to assess the safety and tolerability of fosfomycin/tobramycin for inhalation (FTI) in subjects with cystic fibrosis (CF) or bronchiectasis (BE). Pediatr Pulmonol 2008(Suppl 31):320-1. Abstract 337
59. Geller DE, Flume P, Schwab R, et al. A Phase 1 safety, tolerability and phar-macokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients. Pediatr Pulmonol 2008(Suppl 31):315. Abstract 321
60. Griffith DC, Hansen C, Pressler T, et al. Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cysticfibrosis patients: PK-PD implications. J Cyst Fibros 2008;7:S26. Abstract 104
61. Bruinenberg P, Otulana B, Blanchard J, et al. The effect of once-a day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr Pulmonol 2008(Suppl 31):344. Abstract 401
62. Dupont L, Minic P, Fustik S, et al. A randomized, placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cyst Fibros 2008;7:S26. Abstract 102
63. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharma-codynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53:3847-54
64. Hubert D, Leroyb S, Nove-Josserand R, et al. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cysticfibrosis. J Cystic Fibrosis 2009;8:332-7
65. Denk OL, Coates AL, Leung K, et al. Lung delivery of a new tobramycin nebuliser solution (150mg/1.5mL) by an investigational eFlow nebuliser is equivalent to TOBI but in a fraction of time. J Cystic Fibros 2009;8:S66
66. Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8
67. Hodson ME, Gallagher CG, Govan JRW. A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658-64
68. Hagerman JK, Knechtel SA, Klepser ME. Tobramycin solution for inhalation in cystic fibrosis patients: a review of the literature. Expert Opin Pharmacother 2007;8:467-75
69. Morosini MI, Garcià-Castillo M, Loza E, et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range etest strips. J Clin Microbiol 2005; 43:4480-5
70. Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009; 8:91-6
71. Conway SP, Pond MN, Hamnett T, et al. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33
72. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006; 31:846-58
73. Daniels T. Physiotherapeutic management strategies for the treatment of cystic fibrosis in adults. J Multidiscip Healthc 2010;3:201-12
74. Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140:425-32
75. Abbott J, Havermans T, Hart A. Adherence to the medical regimen: clinical implications of new findings. Curr Opin Pulm Med 2009;15: 597-603
76. Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 2009;75:141-4
77. Abbott J, Dodd M, Bilton D, et al. Treatment compliance in adults with cystic fibrosis. Thorax 1994;49:115-20
78. Poole Arcangelo V, Peterson AM. Principles of pharmacotherapy in pediatrics. In: Pharmacotherapeutics for Advanced Practice: A Practical Approach, 2nd edn. Lippincott Williams & Wilkins, 2006:47
79. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10:54-61
80. O'Malley CA. Infection control in cystic fibrosis: cohorting, cross-contamination, and the respiratory therapist. Respir Care 2009;54:641-55
81. Saiman L, Siegel J, and the Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24:S6-52
82. Blau H, Mussaffi H, Mei Zahav M, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007;33:491-5
83. Lester MK, Flume PA, Gray SL, et al. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care 2004;49:1504-8
84. Rosenfeld M, Emerson J, Astley S, et al. Home nebulizer use among patients with cystic fibrosis. J Pediatr 1998;132:125-31
85. TM technology. J Aero Pulm Med Drug Deliv 2011;24:175-82
86. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009;135:1223-32
87. Konstan MW, Geller DE, Minić P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46:230-8
88. Haynes A, Nakamura J, Heng C, et al. Aerosol performance of tobra-mycin inhalation powder. In Dalby RN, Byron PR, Peart J, et al (eds) Respiratory Drug Delivery 2010. Davis Healthcare Intl Publ, 2010;3:701-6
89. MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiec-tasis. J Antimicrob Chemother 2009;64:829-36
90. Jaffé A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998;351:420
91. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615
92. Steinkamp G, Schmitt-Grohe S, Döring G, et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008;102:1643-53
93. Riethmüller J, Anthonysamy J, Serra E, et al. Therapeutic efficacy and safety of amitryptaline in cystic fibrosis. Cell Physiol Biochem 2009; 24: 65-72
94. Zamorano L, Juan C, Fernández-Olmos A, et al. Activity of the new cepha-losporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. Antimicrob Agents Chemother 2010;54:121-7